Glucose modulates beta cell insulin secretion via effects on ATP-sensitive potassium (KATP) channels. To test the hypothesis that glucose exerts a similar effect on neuronal function, local glucose availability was varied in awake rats using microdialysis in the substantia nigra, the brain region with the highest density of KATP channels. 10 mM glucose perfusion increased GABA release by 111±42%, whereas the sulfonylurea, glipizide, increased GABA release by 84+20%. In contrast, perfusion of the KATP channel activator, lemakalim, or depletion of ATP by perfusion of 2-deoxyglucose with oligomycin inhibited GABA release by 44±8 and 45±11%, respectively. Moreover, the inhibition of GABA release by 2-deoxyglucose and oligomycin was blocked by glipizide.
Introduction
A group of potassium channels has been shown to be sensitive to alterations in the intracellular concentration of ATP and the tionship between sulfonylureas and KATP channels is not known.
However, the channel forms a single functional moiety with the sulfonylurea receptor in neurons (8) , and using autoradiography of labeled sulfonylureas the distribution of KATP channels has been indirectly mapped. Sulfonylurea binding sites are widely distributed throughout the brain and in the rodent are most abundant in the substantia nigra pars reticulata (9) (10) (11) (12) (13) (14) .
ATP-sensitive potassium channels have been best characterized in the endocrine pancreas where they mediate the effect of glucose on insulin release from /3 cells. In vitro experiments have demonstrated that the channels are inhibited by high levels of glucose as well as by sulfonylureas resulting in depolarization and insulin release (15, 16) . In contrast, when intracellular levels of ATP and/or the ATP/ADP ratio falls, KATP channels are activated, leading to hyperpolarization and inhibition of insulin release (17) (18) (19) . In the heart these channels mediate in part the vasodilatory response to hypoxia (4, 20) . However, the role of these channels in neurons is less evident. It has been postulated that KATP channels may mediate responses to ischemia and hypoxia (21) (22) (23) and may perhaps control neuronal excitability and seizure generation (24) .
Of interest is the hypothesis of Lazdunski and his colleagues (24) that the KATP channel may be a direct link between intermediary metabolism and neuronal excitability. They postulated that since these channels are highly expressed presynaptically in the GABAergic pallidonigral projection to the substantia nigra pars reticulata that hypoglycemia by depleting intracellular ATP would open the KATP channels, hyperpolarizing these inhibitory GABA terminals, thereby producing disinhibition of the ascending mesostriatal dopamine pathway (24) . Although seizures do not generate from the substantia nigra, this nucleus appears to have a major gating role in convulsive seizures. A critical level of GABA within the substantia nigra appears necessary to prevent seizure generalization (25, 26) . This theory is attractive as it would explain the association between hypoglycemia and clinical seizures.
To test this hypothesis directly we used microdialysis to alter local glucose availability and to pharmacologically characterize the effects of specific KATP channel agonists and antago-nists on GABA release in vivo. Moreover, we also investigated the effect of systemic hypoglycemia using the insulin-clamp method on both nigral GABA and striatal dopamine release in the freely moving rat.
Methods

Animals
Male Sprague-Dawley rats (weighing 280-300 g) were used for all experiments. Animals were grouped housed in an animal facility with controlled lighting (12-h light/dark cycle) and humidity and ad libitum access to water and standard rat chow (Prolab 3000, comprising of 22% protein, 5% fat, and 51% carbohydrate; Agway, Waverly, NY). On the evening before study, the rat chow was removed and animals were allowed free access to water only.
Microdialysis
Freely moving microdialysis was performed as described previously (27, 28) . In brief, groups of animals were implanted with guide cannulae for placement of concentric microdialysis probes at least 1 wk before dialysis perfusion. In one group of rats the cannula was implanted above the right substantia nigra (AP 3.5, ML 2.15, DV -6 from lambda, flat skull [29] ) to alter glucose availability and to pharmacologically manipulate KATP channels locally. The second group had both the nigra guide cannula as well as a second cannula implanted above the ipsilateral corpus striatum at coordinates relative to bregma, AP 1.2, ML 2.6, DV -3 (29) . These animals underwent insulin hypoglycemic studies as described below. The nigral microdialysis probes were of concentric design, with 2 mm of exposed membrane spanning DV coordinates of 7 to 9 mm from the bregma-lambda plane. The striatal probes were constructed similarly, but used 4 mm of exposed membrane, which after implantation spanned DV coordinates of 3 to 7 mm from the bregmalambda plane.
All probes were inserted via the previously implanted guide cannulae 18-24 h before the microdialysis study. The probes were connected using vitreous silica tubing to 1-ml Hypoglycemic insulin-clamp study 5 d before study, a group of rats underwent aseptic surgery for placement of catheters in both the internal jugular and carotid artery under intraperitoneal Nembutal anesthesia (30 mg kg-'). The polyethylene carotid artery catheter was extended to the level of the aortic arch and the silicone internal jugular vein catheter was advanced to the level of the right atrium. The catheters were filled with heparin (42 U/ml) and polyvinylpyrrolidone (1.7 mg/ml) solution, then plugged and tunneled subcutaneously around the side of the neck and externalized posteriorly through a skin incision. Only animals that recovered from surgery with normal motor and ingestive behavior were used for further study.
On the morning of the experiment, the catheters were flushed with 0.9% saline and maintained patent by slow perfusion of saline (containing 1 U/ml heparin) at 8 yl/min. Animals were awake and freely moving throughout the study. After a 60-min rest period, blood samples were withdrawn for measurement of baseline glucose. At time 0, a continuous infusion of insulin was started (regular porcine insulin; Eli Lilly & Co., Indianapolis, IN) and maintained for 120 min. The perfusion rate ranged from 75 to 80 pmol/kg min-'. Plasma glucose was determined every 5 min throughout the insulin infusion and a variable infusion of 25% dextrose (in sterile water) was adjusted to maintain a stable hypoglycemic plateau. Thereafter the insulin was discontinued and the plasma glucose was raised to baseline values over a 30-min period. For a 120-min period before, during, and for a 80-min period after the insulin infusion, nigral and striatal dialysate were monitored for GABA and dopamine, respectively.
Analysis
Glucose. Plasma glucose was measured using a Beckman Glucose Analyzer II (Beckman Instruments, Inc., Fullerton, CA). Dialysate glucose was measured using an isocratic HPLC system using a 150 X 3-mm phase II 3-Mm ODS analytical column linked directly to a glucose oxidase enzyme reactor with H202 detected on a platinum electrode at 450 mV (BAS 200; BAS Bioanalytical Systems, Inc., West Lafayette, IN). The mobile phase consisted of 50 mM sodium phosphate buffer (pH 8.5) with 0.5% Kathon reagent microbiocide (BAS, West Lafayette, IN) and was pumped at 0.6 ml/min.
GABA. GABA was measured using an isocratic HPLC system with fluorometric detection based on the method of Durkin (32) . The mobile phase consisted of 0.57 M acetic acid (pH 3.78) with 25% acetonitrile and 12% tetrahydrofuran. An AD1O HPLC pump (Shidmazu Scientific Instruments, Inc., Columbia, MD) pump was used isocratically at 0.6 ml/min with separation on a 150 x 3-mm, 3-tum ODS column (Keystone Scientific, Inc., Bellefonte, PA). Fluorometric detection was obtained using a Shidmazu model 551 detector (excitation 330 nm, emission 440 nm). 5 ILI of the dialysis sample was derivatized with 3 pl of an o-pthaladehyde/mercaptopropionic acid reagent and 7.5 Il was injected after a 90-s reaction time using a refrigerated autoinjector (CMA200; Carnegie Medicine, Stockholm, Sweden). A stock reagent was made monthly by adding 10 mg o-pthaladehyde to 4.5 ml methanol and 0.5 ml of a 0.5 mM borate (pH 9.5) buffer to which 25 y1 of mercaptopropionic acid was added. The working reagent was made daily of 100 Itl of methanol, 100 kil of borate buffer, and 36 j1 of the stock reagent.
Statistics
All data are reported as the mean±standard error of the mean (SEM). All comparisons were made using the Systat v. 5 ciency (the ratio of dialysate concentration to absolute ECF concentration) at 1 Ml/min.
Increasing dialysate glucose to 10 mM resulted in a net flux of glucose from the dialysate into brain; the dialysis outflow concentration was -8 mM. Over 60 min of microdialysis perfusion, -0.18 Amol of glucose was delivered locally,raising ECF glucose levels to -10 mM at the outer membrane of the probe, with a gradient to resting level (-1.4 mM as determined above) over several hundred microns radiating from the dialysis membrane (33) . This increase in local ECF glucose resulted in a 111±42% increase in nigral dialysate GABA concentrations from basal levels of 37±3 nM (P < 0.01) (Fig. 1 a) .
Effect of local perfusion with 2-deoxyglucose and oligomycin. The microdialysis probe was perfused with 2-deoxyglucose and oligomycin B. The concentrations used have been shown previously to block glucose metabolism and deplete tissue ATP levels (24) . Dialysate concentrations of GABA decreased with a nadir of 44±8% below basal values reached at 60 min (Fig.  1 b) . Effect of local perfusion of glipizide and lemakalim. The KATP channel antagonist, glipizide, increased dialysate GABA, reaching peak levels of 84±20% above baseline (P < 0.01) at 60 min (Fig. 2 a) . In contrast, the KAW channel agonist, lemakalim, promptly reduced dialysate GABA concentrations measured from the nigral probe. Dialysate GABA concentrations declined by 45±11% (P < 0.0(1) at 30 min (Fig. 2 b) . At the end of the 60-min drug perfusion period, dialysate GABA rapidly returned to baseline values, regardless of whether an agonist or antagonist was used. In addition, glipizide was locally perfused for 150 min, and after 90 min 2-deoxyglucose and oligomycin were added during the final 60 min of the study. In the initial phase, glipizide increased dialysate GABA from 38±3 to 51±5 nM (P < 0.05). The subsequent addition of 2-deoxyglucose and oligomycin had no inhibitory effect on nigral GABA release (Fig. 3) .
Effect ofsystemic hypoglycemia. Before the combined intravenous insulin/glucose infusion basal glucose levels averaged 5.4±0.3 mM. During of 100 min (Fig. 4 a) . Dialysate GABA levels progressively decreased after the start of the insulin infusion. The GABA concentration nadir was reached 30 min before the end of the hypoglycemic period, amounting to a decrease of 49±4% below basal levels (Fig. 4 b) . In contrast, striatal dopamine levels increased reaching a peak at 75 min, an increase of 119±18% above basal values (Fig. 4 c) .
Discussion
These data suggest that glucose availability influences in vivo GABA release via KATP channels and that glucose is not merely a metabolic fuel in the brain but has a direct effect on neurotransmission. Microdialysis perfusion of 1.4±0.3 mM glucose resulted in no net flux of glucose into the brain, an estimate of absolute (spatially averaged) extracellular glucose (30, 31) . This level of glucose was 26±6% that of the fasting plasma levels. Siesjo (34) and Lund-Andersen (35) have proposed that brain ECF glucose levels are 2-4 mM similar to cerebrospinal fluid levels of glucose. Our data suggest that ECF glucose is significantly lower than cerebrospinal fluid levels. Moreover, using microdialysis in conscious humans (36-38) we obtained dialysate levels of glucose of 500 ,M with absolute extracellular levels determined by the no net transfer method (30) of 1.4-1.7 mM when fasting plasma glucose was stable at 4.7-5.6 mM.
The perfusion of 10 mM glucose resulted in a net flux of glucose into the brain ECF. This local delivery of glucose resulted in an increase in nigral GABA release. In contrast, local perfusion of 2-deoxyglucose and oligomycin at concentrations shown to produce depletion of ATP (24) resulted in a significant reduction in GABA release. This pattern of stimulated GABA release to high concentrations of glucose and inhibition of release with low glucose confirms in vitro data using slices of rat substantia nigra (24) . Moreover, our results using drugs which act on the KATP channel are consistent with previously described (41) . Although the effect of hypoglycemia on dopaminergic neuron firing has not been reported, biochemical studies have shown that hypoglycemia increases striatal dopamine turnover (42) . In contrast, chronic hyperglycemia as obtained in diabetic rats reduces nigrostriatal dopamine turnover (43) .
Our data thus suggest that changes in intermediary metabolism and specifically the brain availability of glucose and its extracellular concentration influence neuronal function. Although our data strongly suggest that low glucose and depletion of ATP inhibits GABA release via an action on ATP-sensitive potassium channels, it is possible that the effect of high glucose on GABA release may occur independently of KATP channels. For example, glucose might act in a nonspecific manner as a nutrient, although the mechanism of how such a nutrient effect would translate to neurotransmitter release is unknown. A glucose-stimulated increase in ECF GABA would still require the involvement of a release apparatus including presumably an effect on channel opening or conductance resulting in membrane depolarization. Alternatively, glucose might affect GABA uptake, although there are no data that GABA transporters are inhibited by elevated glucose or increased ATP. Our interpretation that elevated glucose increases transmitter release via KATP channels is also consistent with the neurochemical in vitro data (24) . Of interest are recent data by van der Kuil and Korf (44) and Fellows and Boutelle (45) of changes in extracellular glucose associated with an alteration in neuronal activity. Specifically, van der Kuil reported an increase in hippocampal glucose associated with restraint stress in rodents, whereas Fellows and Boutelle showed that local neuronal depolarization with veratridine lowered extracellular glucose,whereas tetrodotoxin (which acts to block action potentials) increased extracellular glucose. These data suggest that glucose may act as a paracrine factor in the ECF and that dynamic changes in the level of extracellular glucose by local neuronal activity provide an additional mechanism to modulate local brain function. Our data suggest that an increase in extracellular glucose resulting from decreased neuronal activity might increase intraneuronal ATP/ ADP ratios and block KATP channels, thereby resulting in depolarization and neurotransmitter release. The effect on brain function of such elevation, and reciprocally the effect of low glucose, would be dependent on the cellular location of these KATP channels. Specifically the presence of the KATP channels on presynaptic GABA terminals would produce hyperexcitability and lower the seizure threshold during hypoglycemia (and low brain interstitial glucose concentrations), whereas elevated interstitial glucose concentrations would produce increased inhibition. Although this hypothesis supports the association of clinical seizures precipitated by hypoglycemia, KATP channels are expressed in excitatory neurons ( 13) in addition to their expression on inhibitory GABAergic neurons. The net effect on neuronal excitability of alterations in systemic glucose availability might reflect the relative abundance of these channels on inhibitory (GABA) neurons versus excitatory (predominantly glutamatergic) neurons. The intracerebroventricular administration of KATP channel activators exhibits significant antiepileptic activity (46, 47) . This effect is unlikely to be mediated by hyperpolarization and inhibition of nigral GABA release but it is consistent with expression of KATP channels on excitatory, glutamatergic neurons (13, 48) . Although expression of KATP channels in primates in general parallels the expression in rodents (12) , the heterogeneity of expression is much less, suggesting these channels have a more global action in the primate brain.
In summary our data suggest that pharmacological manipulation of the ATP-sensitive potassium channel affects nigral GABA release in vivo. Furthermore, alterations in brain glucose availability influence both GABA and striatal dopamine release in vivo, an effect which may in part be mediated via KATP channels. As brain interstitial glucose levels inversely correlate with neuronal activity in both rodent (49) and human brain (During, M. J., unpublished data), these channels may function largely in a homeostatic manner, with increased neuronal activity depleting interstitial glucose, decreasing the intracellular ATP/ADP ratio, and thereby opening the KATP channel and hyperpolarizing the neuron. This hypothesis is consistent with recent data showing protection of global ischemia-induced neuronal death by centrally administered potassium channel openers (50) .
